Stockscreener 앱 받기
1.115
1.82%
0.015
전일 마감가:
$1.10
열려 있는:
$1.1
하루 거래량:
581.35K
Relative Volume:
0.22
시가총액:
$91.73M
수익:
$65,300
순이익/손실:
$-84.93M
주가수익비율:
-0.6528
EPS:
-1.708
순현금흐름:
$-83.57M
1주 성능:
+4.67%
1개월 성능:
-20.57%
6개월 성능:
-45.63%
1년 성능:
-46.15%
1일 변동 폭
$1.10
$1.15
1주일 범위
$1.06
$1.15
52주 변동 폭
$1.03
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.115 | 90.50M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
442.63 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
610.76 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
905.57 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.30 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.09 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Piper Sandler | Overweight |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-01-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
Inovio Pharmaceuticals(INO) Stock Options Chain | Quotes & News - Moomoo
Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INO stock edges up after hours as partner reports success in cervical dysplasia trial - MSN
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
INOVIO PHARMACEUTICALS INC (INO) Stock Chart - ChartMill
Anal Cancer Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | Incyte Corp, BioMimetix, Inovio Pharma, Merck Sharp & Dohme, Dustin Deming, Advaxis - Barchart.com
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm - Morningstar
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio gains on late-stage trial win for DNA shot - MSN
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
INO Stock Price, Quote & Chart | INOVIO PHARMACEUTICALS INC (NASDAQ:INO) - ChartMill
Inovio Pharma Is Maintained at Neutral by HC Wainwright & Co. - Moomoo
Inovio Shares Fall After Analyst Cut, Traders Wait for FDA Decision - Bez Kabli
INO Maintained by HC Wainwright & Co. -- Price Target Lowered to $2.50 - GuruFocus
H.C. Wainwright lowers Inovio stock price target on share count - Investing.com UK
H.C. Wainwright lowers Inovio stock price target on share count By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Cuts Target Price to $2.5 - Moomoo
INOVIO Partner Reports Phase 3 Success for HPV Therapy in China - MyChesCo
Inovio Pharmaceuticals shareholders back board as INO-3107 FDA review advances - MSN
Q2 2025 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q4 2024 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
INOVIO to Participate in Upcoming Scientific and Investor Conferences - marketscreener.com
Rare disease DNA medicine on agenda as INOVIO hits June conferences - Stock Titan
Inovio Pharmaceuticals (INO) Holds Near Support Amid Slight DeclineReversal Setup Alerts - thelegaladvocate.com
Inovio Brass Hit With Suit Over FDA Approval Claims - Law360
Is Inovio Pharmaceuticals (INO) a High-Stakes Bet Ahead of its October PDUFA Date - Kavout
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances - Yahoo Finance
Inovio Pharmaceuticals (INO) Stock Rises on Positive Trial Resul - GuruFocus
Inovio Pharmaceuticals (INO) Shares Rise on Positive Trial Resul - GuruFocus
Inovio gains on late-stage trial win for DNA shot (INO:NASDAQ) - Seeking Alpha
Piper Sandler Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China - Sahm
Positive Phase 3 Results for Inovio (INO) Partnered VGX-3100 in China - GuruFocus
INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial - Stocktwits
ApolloBio reports positive phase 3 results for VGX-3100 in China - Investing.com UK
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
1.04%
자본화:
|
볼륨(24시간):